Clinical trials: Infantile Hemangioma
Port-Wine Stain
Tolerability of 532 nm Laser Treatment of Port Wine Stains
The goal of this study is to learn about treatment of port wine birthmarks treated with an FDA-approved 532 nm laser. The main questions it aims to answer are: How well are the treatments tolerated? Are there differences in…
- Trial name
- NCT05841628
- Testing
- 532 nm laser treatment
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Massachusetts General Hospital
Infantile Hemangioma, Capillary Hemangioma
A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China
Infant hemangioma(IH) is the most common benign vascular tumor of infancy with the estimated incidence varies 1% to 12%.However, in China, the incidence of infant hemangioma and related epidemiological data remains unclear.
- Conditions
- Infantile Hemangioma, Capillary Hemangioma, Capillary Hemangiomas, Hemangioma, Capillary Infantile
- Trial name
- IH (NCT03173352)
- Where
- China
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Zhujiang Hospital
Infantile Hemangioma (IH)
Abrupt Discontinuation Versus Gradual Tapering of Propranolol in Infantile Hemangioma
Infantile hemangioma is the most common benign vascular tumor in infancy. Oral propranolol is the first-line systemic treatment for infantile hemangiomas requiring therapy.
- Trial name
- PROIHSTOP (NCT07665177)
- Testing
- Abrupt Discontinuation of Propranolol, Gradual Tapering of Propranolol
- Where
- China
- Volunteers
- 110 people
- Sponsor
- West China Hospital
Nevus Flammeus
Treatment of Nevus Flammeus With Alexandrite Laser
Nevus flammeus is a congenital vascular malformation. Nevus flammeus is traditionally treated with pulsed dye lasers (PDL); however, around 20 percent of patients are poor responders and do not get satisfactory results from…
- Trial name
- NCT01968681
- Testing
- Alexandrite laser
- Where
- Denmark
- Volunteers
- 19 people
- Sponsor
- Bispebjerg Hospital
Von Hippel-Lindau Syndrome, Renal Cell Carcinoma
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
The goal of this clinical research study is to learn if sunitinib malate (SU011248) can help to control VHL. The safety of this drug will also be studied.
- Conditions
- Von Hippel-Lindau Syndrome, Renal Cell Carcinoma, Hemangioblastoma
- Trial name
- NCT00330564
- Testing
- SU011248
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Port-Wine Stain
Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain
This study is to provide safety information of hemoporfin during the post-marketing period as required by China Food and Drug Administration (CFDA) regulations in order to identify any potential drug related treatment factors in…
- Trial name
- NCT03181984
- Testing
- Hemoporfin
- Where
- 7 sites in China
- Volunteers
- 501 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Infantile Hemangioma
Study to Demonstrate the Efficacy and Safety of Propranolol Oral Solution in Infants With Proliferating Infantile Hemangiomas Requiring Systemic Therapy
There is an unsatisfied medical need for a first-line treatment of proliferating IHs with a good benefit/risk profile. Based on the recent findings of encouraging results obtained with propranolol in a series of infants with…
- Trial name
- NCT01056341
- Testing
- Propranolol
- Where
- 59 sites in United States, Australia and 14 more
- Volunteers
- 512 people
- Sponsor
- Pierre Fabre Dermatology
Hemangioma, Capillary
A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy
Hemangiomas of infancy, the most common benign tumors of infancy, are congenital or early infancy lesions characterized by a rapid postnatal growth, with high expression of angiogenic stimulators for 9-18 months, followed by slow…
- Trial name
- NCT00601016
- Testing
- Imiquimod 5% cream
- Where
- Canada
- Volunteers
- 18 people
- Sponsor
- St. Justine's Hospital
Port-Wine Stain
Novel Treatment for Port Wine Stain Birthmarks
Port wine stains Birthmark are congenital, progressive vascular malformations of the skin that occur in approximately 0.7% of newborns.
- Trial name
- NCT01924273
- Testing
- Talaporfin sodium
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, Irvine
Lipoma, Branchial Cleft Anomalies
Radiological Diagnosis of Pediatric Neck Swellings
Various diagnostic imaging modalities have been utilized in the assessment of pediatric neck lesions, including gray-scale and Doppler ultrasonography, conventional and three-dimensional computed tomography (CT), magnetic…
- Conditions
- Lipoma, Branchial Cleft Anomalies, Cystic Hygroma (Macro-cystic Lymphatic Malformation), Rhabdomyosarcoma
- Trial name
- NCT07734805
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Sohag University
Port Wine Stain
A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.
The researchers want to collect data on safety and efficacy of combined pulsed dye laser and rapamycin to improve fading/blanching of port wine stain birthmarks as compared to pulsed dye laser alone, which is the current standard…
- Trial name
- NCT00830466
- Testing
- Laser and rapamycin versus laser alone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, Irvine
Infantile Hemangiomas
Timolol Option for Ulcerated Hemangiomas (TOUCH Trial)
The purpose of this study is to determine whether Timolol 0.5% Gel Forming Solution is safe and effective in promoting wound healing of infantile ulcerated hemangiomas compared with standard conservative management with topical…
- Trial name
- TOUCH (NCT01408056)
- Testing
- Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment
- Where
- United States
- Sponsor
- Children's Hospital of Philadelphia
Port Wine Stain
A Randomized Trial to Study Combined Pulsed Dye Laser and Rapamycin Treatment of Port Wine Stain Birthmarks.
The purpose of this study is to improve port wine stain therapeutic outcome in response to laser therapy. The researchers want to determine whether the combined use of pulsed dye laser therapy and rapamycin will improve PWS…
- Trial name
- NCT00800722
- Testing
- Rapamycin Treatment of Port Wine Stain
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of California, Irvine
Hemangioblastoma, Hippel Lindau Disease
Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease
The purpose of this study is to learn more about the growth of brain and spinal cord tumors and cysts that develop in association with them in patients with von Hippel-Lindau disease.
- Trial name
- NCT00005902
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Von Hippel-Lindau Syndrome
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Background: People with Von-Hippel-Lindau (VHL) disease may experience significant vision loss as a result of retinal capillary hemangiomas (RCH), the most common and often earliest manifestation of VHL.
- Trial name
- NCT02859441
- Testing
- Ranibizumab, E10030
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Eye Institute (NEI)
Port-wine Stain
A Pilot Study of Hemoporfin PDT in Children(2-7 Years Old) With Port-wine Stain
This pilot study aims to evaluate the safety and efficacy of hemoporfin photodynamic therapy (PDT) with different light doses for port-wine stain (PWS）in 2-7 years old children.
- Trial name
- NCT04106258
- Testing
- Hemoporfin PDT
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Port Wine Stain
Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
Port wine stains are red birthmarks that without treatment persist for a lifetime. They are frequently found on the face and can be conspicuous and disfiguring, negatively impacting social interactions for these patients.
- Trial name
- Aldara (NCT00585247)
- Testing
- Imiquimod
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of California, Irvine
Port-Wine Stain
Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment
Port wine stain Birthmark is a congenital, progressive vascular malformation of human skin. However, even though the pulsed dye laser is considered as the treatment of choice for Port wine stain Birthmark the degree of fading can…
- Trial name
- NCT01775722
- Testing
- Pulsed Dye Laser, Combined Bipolar Radiofrequency&Pulsed Dye Laser
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of California, Irvine
Port Wine Stains
Lip Reduction Surgery for Port-wine Macrocheilia
Patients with port-wine stains often develop macrocheilia, however, there is currently no effective treatment to significantly reduce the three-dimensional volume increase of the lips.
- Trial name
- macrocheilia (NCT07128459)
- Testing
- The Five-Step lip reduction surgery
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Von Hippel-Lindau Disease
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
Background: Von Hippel-Lindau (VHL) disease is a rare gene disease. People with VHL often have a brain tumor called hemangioblastoma. Standard treatment for these tumors is risky surgery.
- Trial name
- NCT02108002
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)